Literature DB >> 6983972

Clearance of interleukin 2 from the blood of normal and T cell-depleted mice.

P F Mühlradt, H G Opitz.   

Abstract

Partially purified, concentrated interleukin 2 (IL 2) was injected i.v. into normal and T cell-depleted mice. At various times after injection IL 2 was determined in the sera of these mice. An interference with the test by a potential inhibitor of IL 2 in the serum was excluded. Il 2 was cleared equally rapidly, with a half-life of 3 min, from the blood of both groups of mice. It is concluded that IL 2 is a short-range mediator under physiological conditions, and that clearance was not due to adsorption to T cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6983972     DOI: 10.1002/eji.1830121117

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Authors:  Alice Tzeng; Byron H Kwan; Cary F Opel; Tejas Navaratna; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

2.  Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model.

Authors:  N V Katre; M J Knauf; W J Laird
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

3.  Serum IL-2 inhibitor in mice. II. Molecular characteristics.

Authors:  D Male; R Lelchuk; S Curry; G Pryce; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

4.  Therapeutic use of interleukins: experimental results.

Authors:  R D Granstein; A Tominaga; M I Greene
Journal:  Surv Immunol Res       Date:  1984

5.  Armed CD4+ Th1 effector cells and activated macrophages participate in bile duct injury in murine biliary atresia.

Authors:  Cara L Mack; Rebecca M Tucker; Ronald J Sokol; Brian L Kotzin
Journal:  Clin Immunol       Date:  2005-05       Impact factor: 3.969

6.  Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.

Authors:  K Y Tsang; H H Fudenberg; G M Galbraith; R P Donnelly; L R Bishop; W R Koopmann
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  The in vivo functions and properties of persisting cell-stimulating factor.

Authors:  R M Crapper; I Clark-Lewis; J W Schrader
Journal:  Immunology       Date:  1984-09       Impact factor: 7.397

Review 8.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

9.  Tumour inhibitory effects of TCGF/IL-2/-containing preparations.

Authors:  J Bubeník; M Indrová; P Perlmann; K Berzins; O Mach; J Kraml; A Toulcová
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Quantitative absorption of interleukin-2 by peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis.

Authors:  C Knobloch; M Schlesier; R Dräger; M Gärtner; H H Peter
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.